| Detected | Trial | Change |
|---|---|---|
| 2026-08-05 | NCT05168163 Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of… |
date change Primary completion pushed: 2025-12-31 -> 2026-06-30 |
| 2026-08-02 | NCT02949219 Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or… |
overall status: Active, Not Recruiting → Unknown |
| 2026-07-19 | NCT03012100 Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in… |
Primary endpoint(s) modified |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 2 | |||
| NCT06238648 | Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete… | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Recruiting |
| NCT05910801 | Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory… | Recurrent Mantle Cell Lymphoma | Recruiting |
| NCT06160206 | Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of… | Recurrent Glioblastoma | Recruiting |
| NCT05168163 | Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of… | Locally Advanced Hepatocellular Carcinoma | Recruiting |
| NCT04756401 | Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk… | Recurrent Plasma Cell Myeloma | Active, Not Recruiting |
| NCT04117945 | Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally… | BRAF V600E Negative | Active, Not Recruiting |
| NCT02758717 | Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin… | Ann Arbor Stage IB Hodgkin Lymphoma | Active, Not Recruiting |
| NCT05246670 | PEA for the Relief of Chemotherapy-Induced Peripheral Neuropathy | Chemotherapy-Induced Peripheral Neuropathy | Active, Not Recruiting |
| NCT03233347 | Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating… | Ann Arbor Stage I Hodgkin Lymphoma | Active, Not Recruiting |
| NCT04042831 | Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA… | Bile Duct Adenocarcinoma | Active, Not Recruiting |
| NCT03012100 | Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in… | Bilateral Breast Carcinoma | Active, Not Recruiting |
| NCT05194293 | Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer | Stage IB Hepatocellular Carcinoma AJCC v8 | Active, Not Recruiting |
| NCT04626791 | Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of… | Mantle Cell Lymphoma | Active, Not Recruiting |